# KAPA (Kairos Pharma, Ltd.) - SEC EDGAR Financial Statements

> Kairos Pharma, Ltd. reported $4.37M in total assets and a net loss of $6.39M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/KAPA
- Markdown: https://convexityos.com/fundamentals/KAPA.md
- SEC CIK: 0001962011
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:12 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001962011&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$6.53M | Operating profit |
| Net Income | FY 2025 | -$6.39M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$1.91 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $3.12M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Research & Development | $2.13M | $414K | $82K |
| Total Operating Expenses | $5.57M | $2.34M | $1.71M |
| **Operating Income** | -$5.57M | -$2.34M | -$1.71M |
| Interest Expense | -- | $35K | $42K |
| **Net Income** | -$5.45M | -$2.60M | -$1.81M |
| Basic EPS | -$2.10 | -$1.61 | -$1.19 |
| **Diluted EPS** | -$2.10 | -$1.61 | -$1.19 |
| Basic Shares Outstanding | 2.6M | 1.6M | 1.5M |
| Diluted Shares Outstanding | 2.6M | 1.6M | 1.5M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $892K | $619K | $684K | $538K | $608K | $496K | $493K | $172K |
| Total Operating Expenses | $2.01M | $1.42M | $1.69M | $1.42M | $1.44M | $1.46M | $1.27M | $1.45M |
| **Operating Income** | -$2.01M | -$1.42M | -$1.69M | -$1.42M | -$1.44M | -$1.46M | -$1.27M | -$1.45M |
| Interest Expense | -- | -- | -- | -- | -- | -- | -- | $0 |
| **Net Income** | -$1.98M | -$1.39M | -$1.65M | -$1.36M | -$1.40M | -$1.42M | -$1.26M | -$980K |
| Basic EPS | -$0.59 | -$0.42 | -$0.56 | -- | -$0.48 | -$0.56 | -$0.56 | -- |
| **Diluted EPS** | -$0.59 | -$0.42 | -$0.56 | -- | -$0.48 | -$0.56 | -$0.56 | -- |
| Basic Shares Outstanding | 3.3M | 3.1M | 3.0M | -- | 2.9M | 2.5M | 2.3M | -- |
| Diluted Shares Outstanding | 3.3M | 3.1M | 3.0M | -- | 2.9M | 2.5M | 2.3M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $4.49M | $1.27M | $93K |
| **Cash & Short-Term Investments** | $4.49M | $1.27M | $93K |
| **Total Current Assets** | $5.39M | $4.17M | $101K |
| Intangible Assets | $62K | $222K | $382K |
| **Total Non-Current Assets** | $1.15M | $1.60M | $864K |
| **Total Assets** | $6.54M | $5.77M | $965K |
| **Total Current Liabilities** | $199K | $992K | $2.40M |
| **Total Non-Current Liabilities** | $0 | $0 | $638K |
| **Total Liabilities** | $199K | $992K | $3.04M |
| Common Stock | $3.0K | $14K | $11K |
| Retained Earnings | -$14.26M | -$8.81M | -$6.21M |
| **Total Stockholders' Equity** | $6.34M | $4.78M | -$2.08M |
| Total Equity | $6.34M | $4.78M | -$2.08M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $3.12M | $2.63M | $3.67M | $4.49M | $5.58M | $3.03M | $3.62M | $1.27M |
| **Cash & Short-Term Investments** | $3.12M | $2.63M | $3.67M | $4.49M | $5.58M | $3.03M | $3.62M | $1.27M |
| **Total Current Assets** | $3.35M | $3.17M | $4.44M | $5.39M | $6.66M | $4.84M | $6.05M | $4.17M |
| Intangible Assets | -- | $191K | $22K | $62K | $102K | $142K | $182K | $222K |
| **Total Non-Current Assets** | $1.02M | $1.28M | $1.30M | $1.15M | $1.41M | $1.83M | $1.89M | $1.60M |
| **Total Assets** | $4.37M | $4.46M | $5.74M | $6.54M | $8.07M | $6.67M | $7.94M | $5.77M |
| **Total Current Liabilities** | $495K | $265K | $431K | $199K | $402K | $676K | $805K | $992K |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $495K | $265K | $431K | $199K | $402K | $676K | $805K | $992K |
| Common Stock | $4.0K | $21K | $21K | $3.0K | $21K | $18K | $16K | $14K |
| Retained Earnings | -$19.29M | -$17.30M | -$15.92M | -$14.26M | -$12.90M | -$11.50M | -$10.08M | -$8.81M |
| **Total Stockholders' Equity** | $3.88M | $4.19M | $5.31M | $6.34M | $7.66M | $6.00M | $7.13M | $4.78M |
| Total Equity | $3.88M | $4.19M | $5.31M | $6.34M | $7.66M | $6.00M | $7.13M | $4.78M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$5.45M | -$2.60M | -$1.81M |
| **Operating Cash Flow** | -$3.44M | -$3.96M | $81K |
| **Financing Cash Flow** | $6.66M | $5.13M | -$425K |
| **Net Change in Cash** | $3.22M | $1.18M | -$344K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$1.98M | -$1.39M | -$1.65M | -$1.36M | -$1.40M | -$1.42M | -$1.26M | -$980K |
| **Operating Cash Flow** | -$979K | -$1.01M | -$1.04M | -$1.08M | -$838K | -$805K | -$714K | -$1.80M |
| **Financing Cash Flow** | $1.48M | -$37K | $220K | $0 | $3.38M | $223K | $3.06M | -$142K |
| **Net Change in Cash** | $499K | -$1.05M | -$816K | -$1.08M | $2.54M | -$582K | $2.34M | -$1.95M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Return on Equity (ROE) | -85.9% | -54.5% | -- |
| Return on Assets (ROA) | -83.3% | -45.1% | -187.8% |
| Current Ratio | 27.07x | 4.20x | 0.04x |
| Quick Ratio | 22.57x | 1.28x | 0.04x |
| Operating Cash Flow Growth (YoY) | -- | -4982.7% | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -164.9% | -138.5% | -109.9% | -85.9% | -66.0% | -78.6% | -49.7% | -54.5% |
| Return on Assets (ROA) | -146.2% | -130.3% | -101.7% | -83.3% | -62.8% | -70.6% | -44.6% | -45.1% |
| Current Ratio | 6.77x | 11.98x | 10.31x | 27.07x | 16.56x | 7.16x | 7.52x | 4.20x |
| Quick Ratio | 6.31x | 9.91x | 8.53x | 22.57x | 13.87x | 4.49x | 4.49x | 1.28x |
| Operating Cash Flow Growth (YoY) | -- | -- | -- | -- | -- | -- | -2083.3% | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
